FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897771679> ?p ?o ?g. }

• W2897771679 endingPage "S133" @default.
• W2897771679 startingPage "S133" @default.
• W2897771679 abstract "There is emerging interest in the role of SBRT in locally advanced pancreas cancer, however little prospective data exists examining the safety, efficacy, and optimal target volumes for SBRT in the neoadjuvant setting for resectable or BLR pancreatic cancer. The durability of local control and failure patterns following SBRT in the neoadjuvant setting are not well described. A phase II prospective trial was conducted in resectable and BLR pancreatic patients. Eighteen patients were enrolled from 11/2014-6/2017. All patients received 3 cycles of chemotherapy and restaging prior to radiation. SBRT was delivered to the tumor and abutting vessel with fiducials/compression and a 3 mm PTV margin to 33 Gy (6.6 Gyx5fxn) with an optional elective PTV to 25 Gy (5 Gyx5fxn) customized to the nodal space and mesenteric vessels. Patients without progression underwent surgery 4-6 weeks following SBRT. The primary endpoint is ≥ Grade 3 acute and late GI toxicity. Secondary endpoints included overall survival (OS), progression-free survival (PFS), and cumulative incidence of local failure (LF). LF is defined as recurrence within conventional RT volumes from the time of resection to local failure or last CT with no progression. Local failures were fused to planning CTs for dose quantification. Thirteen patients had BLR tumors due to arterial abutment (n = 7) or SMV encasement (n = 6); 3 patients had resectable tumors. All patients received 4 months of gemcitabine/nab-paclitaxel (n = 13) or FOLFIRNOX (n = 5) prior to SBRT. There were no ≥ Grade 3 acute or late GI events. Following completion of SBRT, 6 patients progressed (33%) at restaging or surgery with liver metastases (n=5, 28%) or local disease (n=1, 5%). Surgery was performed in 12 patients (67%) with 11 (92%) R0 resections (median margin distance 1.75 mm [0-9mm]). Lymph nodes were involved in 4 (33%) patients. Median OS was 21 months for all patients. In patients undergoing resection median OS was 31 months compared to 9 months without resection (p=0.003). The median PFS was 11 months. Progression occurred in 75% (9/12) of resected patients with first site of failure as distant (n = 4, 44%), local only (n = 4, 44%), and local and distant (n = 1,11%). The cumulative incidence of LF at 12 months from resection was 56% with one patient surviving 15 months without LF. All LF were outside to the PTV33 with median D90 of 11.5 Gy (4-25 Gy), V25 Gy of 51% (0-90%), and V33 Gy of 45% (0-52%). In resected patients, LF occurred in 4/8(50%) patients treated with a 25 Gy elective PTV and in 4/5(80%) of patients treated to the primary only (p=0.56). SBRT as a component of neoadjuvant therapy was well tolerated. However, local failures were predominantly observed outside the PTV33 volume within conventional RT volumes. Therefore, the durability of local control after SBRT in the neoadjuvant setting using target volumes and dose as described merits close examination relative to chemoradiation prior to incorporation into routine practice." @default.
• W2897771679 created "2018-10-26" @default.
• W2897771679 creator A5008801653 @default.
• W2897771679 creator A5009788569 @default.
• W2897771679 creator A5011618808 @default.
• W2897771679 creator A5012171015 @default.
• W2897771679 creator A5018387768 @default.
• W2897771679 creator A5031132761 @default.
• W2897771679 creator A5067793731 @default.
• W2897771679 creator A5070290052 @default.
• W2897771679 creator A5081161607 @default.
• W2897771679 creator A5091876744 @default.
• W2897771679 date "2018-11-01" @default.
• W2897771679 modified "2023-09-27" @default.
• W2897771679 title "Phase II Trial of Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy (SBRT) for Resectable and Borderline Resectable (BLR) Pancreas Cancer" @default.
• W2897771679 doi "https://doi.org/10.1016/j.ijrobp.2018.06.328" @default.
• W2897771679 hasPublicationYear "2018" @default.
• W2897771679 type Work @default.
• W2897771679 sameAs 2897771679 @default.
• W2897771679 citedByCount "2" @default.
• W2897771679 countsByYear W28977716792020 @default.
• W2897771679 countsByYear W28977716792021 @default.
• W2897771679 crossrefType "journal-article" @default.
• W2897771679 hasAuthorship W2897771679A5008801653 @default.
• W2897771679 hasAuthorship W2897771679A5009788569 @default.
• W2897771679 hasAuthorship W2897771679A5011618808 @default.
• W2897771679 hasAuthorship W2897771679A5012171015 @default.
• W2897771679 hasAuthorship W2897771679A5018387768 @default.
• W2897771679 hasAuthorship W2897771679A5031132761 @default.
• W2897771679 hasAuthorship W2897771679A5067793731 @default.
• W2897771679 hasAuthorship W2897771679A5070290052 @default.
• W2897771679 hasAuthorship W2897771679A5081161607 @default.
• W2897771679 hasAuthorship W2897771679A5091876744 @default.
• W2897771679 hasBestOaLocation W28977716791 @default.
• W2897771679 hasConcept C121608353 @default.
• W2897771679 hasConcept C126322002 @default.
• W2897771679 hasConcept C126838900 @default.
• W2897771679 hasConcept C141071460 @default.
• W2897771679 hasConcept C168563851 @default.
• W2897771679 hasConcept C203092338 @default.
• W2897771679 hasConcept C2776694085 @default.
• W2897771679 hasConcept C2778764654 @default.
• W2897771679 hasConcept C2780210213 @default.
• W2897771679 hasConcept C2780258809 @default.
• W2897771679 hasConcept C2780387249 @default.
• W2897771679 hasConcept C31760486 @default.
• W2897771679 hasConcept C509974204 @default.
• W2897771679 hasConcept C71924100 @default.
• W2897771679 hasConceptScore W2897771679C121608353 @default.
• W2897771679 hasConceptScore W2897771679C126322002 @default.
• W2897771679 hasConceptScore W2897771679C126838900 @default.
• W2897771679 hasConceptScore W2897771679C141071460 @default.
• W2897771679 hasConceptScore W2897771679C168563851 @default.
• W2897771679 hasConceptScore W2897771679C203092338 @default.
• W2897771679 hasConceptScore W2897771679C2776694085 @default.
• W2897771679 hasConceptScore W2897771679C2778764654 @default.
• W2897771679 hasConceptScore W2897771679C2780210213 @default.
• W2897771679 hasConceptScore W2897771679C2780258809 @default.
• W2897771679 hasConceptScore W2897771679C2780387249 @default.
• W2897771679 hasConceptScore W2897771679C31760486 @default.
• W2897771679 hasConceptScore W2897771679C509974204 @default.
• W2897771679 hasConceptScore W2897771679C71924100 @default.
• W2897771679 hasIssue "3" @default.
• W2897771679 hasLocation W28977716791 @default.
• W2897771679 hasOpenAccess W2897771679 @default.
• W2897771679 hasPrimaryLocation W28977716791 @default.
• W2897771679 hasRelatedWork W1978045769 @default.
• W2897771679 hasRelatedWork W2072714492 @default.
• W2897771679 hasRelatedWork W2128095147 @default.
• W2897771679 hasRelatedWork W2245783872 @default.
• W2897771679 hasRelatedWork W2319496893 @default.
• W2897771679 hasRelatedWork W2340248789 @default.
• W2897771679 hasRelatedWork W2391084975 @default.
• W2897771679 hasRelatedWork W2414965726 @default.
• W2897771679 hasRelatedWork W2600149174 @default.
• W2897771679 hasRelatedWork W3032321783 @default.
• W2897771679 hasVolume "102" @default.
• W2897771679 isParatext "false" @default.
• W2897771679 isRetracted "false" @default.
• W2897771679 magId "2897771679" @default.
• W2897771679 workType "article" @default.